Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas.
Despite many advances in cancer therapy, metastatic disease continues to be incurable in the majority of cancer patients. There is an need for more efficient and less toxic treatments in this setting. Oncolytic virotherapy represents a novel promising direction in the treatment of cancer. Based on preclinical and clinical data, combination with standard chemotherapy has the potential to further increase the antitumor activity of oncolytic virotherapy in a synergistic manner. We present the design of a phase I clinical trial combining intratumoral injections of the oncolytic adenovirus ONYX-015 with systemic chemotherapy in patients with advanced sarcomas.
Opyrchal
Mateusz
M
Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Aderca
Ileana
I
Galanis
Evanthia
E
D000256:Adenoviridae / Q000235:genetics* / Q000502:physiology; D000293:Adolescent; D000328:Adult; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use*; D006801:Humans; D017403:In Situ Hybridization; D007753:Laboratories; D016685:Mitomycin / Q000627:therapeutic use*; D050504:Oncolytic Viruses / Q000235:genetics* / Q000502:physiology; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology* / Q000821:virology; D014765:Viral Vaccines; D014779:Virus Replication
D014765:Viral Vaccines; C464532:dl1520; D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin